Phase I clinical trial with the AMC-bioartificial liver

International Journal of Artificial Organs

Volumn 25, Issue 10, 2002, Pages 950-959

  Van De Kerkhove, M P ^a   Di Florio, E ^b   Scuderi, V ^b   Mancini, A ^b   Belli, A ^b   Bracco, A ^b   Dauri, M ^c   Tisone, G ^c   Di Nicuolo, G ^d   Amoroso, P ^d   Spadari, A ^e   Lombardi, G ^f   Hoekstra, R ^a   Calise, F ^b   Chamuleau, R A F M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b CARDARELLI HOSPITAL   (Italy)

^c S EUGENIO HOSPITAL   (Italy)

^d AO Dei Colli Hospital for Infectious Diseases D Cotugno   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELLA LOMBARDIA E DELL EMILIA ROMAGNA   (Italy)

Author keywords

Acute liver failure; Bioartificial liver; Clinical trial; Hepatocyte; Human; Liver transplantation; Porcine; Safety

Indexed keywords

MAMMALS; PATIENT TREATMENT;

ACADEMIC MEDICAL CENTERS; ACUTE LIVER FAILURE; BIOARTIFICIAL LIVER; CLINICAL TRIAL; HEPATOCYTES; HUMAN; LIVER TRANSPLANTATION; ORTHOTOPIC LIVER TRANSPLANTATION; PHASE I; PORCINE;

ARTIFICIAL ORGANS;

ADULT; ARTICLE; ARTIFICIAL LIVER; BLOOD FILTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMA; CONVALESCENCE; DISEASE SEVERITY; FEASIBILITY STUDY; FEMALE; HUMAN; ITALY; LIVER CELL; LIVER FAILURE; LIVER FUNCTION; LIVER GRAFT; LIVER TRANSPLANTATION; MALE; NETHERLANDS; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PLASMAPHERESIS; POSTOPERATIVE COMPLICATION; RODENT; SAFETY; SWINE; TREATMENT OUTCOME;

EID: 0036816637     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880202501009     Document Type: Article

References (50)

1. Bernuau J, Benhamou J-P. Fulminant and Subfulminant Liver Failure. In: Mc Intyre N, Benhamou J-P, Bircher J, Rizzetto M, Rodes J, eds. Oxford, New York, Tokyo: Oxford University Press, 1991; 923-42.
2. Lidofsky SD, Bass NM, Prager MC, et al. Intracranial pressure monitoring and liver transplantation for fulminant hepatic failure. Hepatology 1992; 16: 1-7.
3. De Rave S, Tilanus HW, Van Der Linden J, et al. The importance of orthotopic liver transplantation in acute hepatic failure. Transpl Int 2002; 15: 29-33.
4. Wall WJ, Adams PC. Liver transplantation for fulminant hepatic failure: North American experience. Liver Transplant Surg 1995; 1: 178-82.
5. Adam R, Cailliez V, Majno P, et al. Normalised intrinsic mortality risk in liver transplantation: European Liver Transplant Registry study. Lancet 2000; 356: 621-7.
6. Keeffe EB. Liver transplantation: Current status and novel approaches to liver replacement. Gastroenterology 2001; 120: 749-62.
7. Eurotransplant data 1998, 1999, 2000. Statistics for liver transplantations 2000 http://www.eurotransplant.nl.
8. Watanabe FD, Mullon CJ, Hewitt WR, et al. Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. Ann Surg 1997; 225: 484-91.
9. Detry O, Arkadopoulos N, Ting P, et al. Clinical use of a bioartificial liver in the treatment of acetaminiophen-induced fulminant hepatic failure. Am Surg 1999; 65: 934-8.
10. Chen SC, Mullon C, Kahaku E, et al. Treatment of severe liver failure with a bioartificial liver. Ann NY Acad Sci 1997; 831: 350-60.
11. Watanabe FD, Mullon CJ, Hewitt WR, et al. Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. Ann Surg 1997; 225: 484-91.
12. Chen SC, Hewitt WR, Watanabe FD, et al. Clinical experience with a porcine hepatocyte based liver support system. Int J Artif Organs 1996; 19: 664-9.
13. Mazariegos GV, Kramer DJ, Lopez RC, et al. Safety observations in phase I clinical evaluation of the Excorp Medical Bioartificial Liver Support System after the first four patients. ASAIO J 2001; 47: 471-5.
14. Sussman NL, Kelly TH. Improved liver function following treatment with an extracorporeal liver assist device. Artif Organs 1993; 17: 27-30.
15. Sussman NL, Gislason GT, Conlin CA, Kelly TH. The Hepatix extracorporeal liver assist device: Initial clinical experience. Artif Organs 1994; 18: 390-6.
16. Sussman NL, Gislason GT, Kelly TH. Extracorporeal liver support. Application to fulminant hepatic failure. J Clin Gastroenterology 1994; 18: 320-4.
17. Ellis AT, Hughes RD, Wendon TA, et al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 1996; 24: 1446-51.
18. Flendrig LM, La Soe TW, Jörning GGA, et al. In vitro evaluation of a novel bioreactor based on an integral oxygenator and a spirally wound nonwoven polyester matrix for hepatocyte culture as small aggregates. J Hepatol 1997; 26: 1379-92.
19. Flendrig LM, Chamuleau RAFM, Maas MAW, et al. Evaluation of a novel design bioartificial liver in rats with complete liver ischemia: Treatment efficacy and species-specific α-GST detection as a first attempt to monitor hepatocyte viability. J Hepatol 1999; 30: 311-20.
20. Flendrig LM, Calise F, Di Flono E, et al. Significantly improved survival time in pigs with complete liver ischemia treated with a novel bioartificial liver. Int J Artif Organs 1999; 22: 701-9.
21. Sosef MN, Abrahamse LSL, Van De Kerkhove M-P, Hartman R, Chamuleau RAFM, Van Gulik TM. Assessment of the AMC-Bioartificial Liver in the anhepatic pig. Transplantation 2002, 73: 204-9.
22. Van Der Laan UW, Lockey C, Griffeth BC, et al. Infection by porcine endogenous retrovirus after islet xenotransplantation. Nature 2000; 407: 90-4.
23. Takeuchi Y, Patience C, Magre S, et al. Host range and interference studies of three classes of pig endogenous retrovirus. J Virol 1998; 72: 9986-91.
24. Herring C, Cunningham DA, Whittam AT, Fernandez-Suarez XM, Langford GA. Monitoring xenotransplant recipients for infection by PERV. Clin Biochem 2001; 34: 23-7.
25. Dixon FJ, Vazquez TT, Weigle WO, et al. Pathogenesis of serum sickness. Arch Pathol 1958: 65: 18-28.
26. Te Velde AA, Flendrig LM, Ladiges NC, Chamuleau RA. Immunological consequences of the use of xenogeneic hepatocytes in a bioartificial liver for acute liver failure. Int J Artif Organs 1997; 20: 229-33.
27. Te Velde AA, Flendrig LM, Ladiges NC, Chamuleau RA. Possible immunological problems of bioartificial liver support (Editorial). Int J Artif Organs 1997; 20: 418-21.
28. Baquerizo A, Mhoyan A, Kearns-Jonker M, et al. Characterization of human xenoreactive antibodies in liver failure patients exposed to pig hepatocytes after bioartificial liver treatment. Transplantation 1999; 67: 5-18.
29. Takahashi M, Ishikura H, Takahashi C, et al. Immunologic considerations in the use of cultured porcine hepatocytes as a hybrid artificial liver. Anti-porcine hepatocyte human serum. ASAIO J 1993; 39: M242-M6.
30. Hasegawa H, Shimada M, Gion T, et al. Modulation of immunologic reactions between cultured porcine hepatocytes and human sera. ASAIO J 1999; 45: 392-6.
31. Te Velde AA, Ladiges NCJT, Flendrig LM, Chamuleau RAFM. Functional activity of isolated pig hepatocytes attached to different extracellular matrix substrates. Implications for application of pig hepatocytes in a bioartificial liver. J Hepatol 1995; 23: 184-92.
32. Relman DA, Schmidt TM, MacDermott RP, Falkow S. Identification of the uncultured bacillus of Whipple's disease. New Engl J Med 1992; 327: 293-301.
33. Van Kuppeveld FT, Van Der Logt TT, Angulo AF, et al. Genus- and species-specific identification of mycoplasmas by 16SrRNA amplification. Appl Environ Microb 1992; 58: 2606-15.
34. Bernuau T, Goudeau A, Poynard T, et al. Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology 1986; 6: 648-51.
35. O'Grady TG, Alexander GT, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 92: 439-45.
36. Riordan SM, Williams R. Experience in design of controlled clinical trials in acute liver failure. In: Crepaldi G, Demetriou AA, Muraca M, eds. Bioartificial Liver Support Systems. The Critical Issues. Rome: CIC Edizioni Internazionali, 1997; 104-15.
37. Conn HO, Lieberthal MM. The Hepatic Coma Syndromes and Lactulose. Baltimore: Williams & Wilkins, 1979.
38. Jalan R, Damink SW, Deutz NE, Lee A, Hayes PC. Moderate hypothermia for uncontrolled intracranial hypertension in acute liver failure. Lancet 1999; 354: 2082.
39. Samuel D, Ichai P, Feray C, et al. Neurological improvement during bioartificial liver sessions in patients with acute liver failure awaiting transplantation. Transplantation 2002; 73: 257-64.
40. Stoves T, Goode NP, Visvanathan R, et al. The bradykinin response and early hypotension at the introduction of continuous renal replacement therapy in the intensive care unit. Artif Organs 2001; 25: 1009-13.
41. Platt JL. "Xenoassistance devices" for the treatment of hepatic failure: Challenges and controversies. Transplant Proc 2000; 32: 2693-95.
42. Gerlach TC, Lemmens P, Schon M, et al. Experimental evaluation of a hybrid liver support system. Transplant Proc 1997; 29: 852.
43. Gerlach TC. Long-term liver cell cultures in bioreactors and possible application for liver support. Cell Biol Toxicol 1997; 13: 349-55.
44. Neuzil DF, Rozga T, Moscioni AD, et al. Use of a novel bioartificial liver in a patient with acute liver insufficiency. Surgery 1993; 113: 340-3.
45. Rozga T, Podesta L, Lepage E, et al. A bioartificial liver to treat severe acute liver failure. Ann Surg 1994; 219: 538-46.
46. Hoekstra R, Chamuleau RAFM. Recent developments of human cell lines for the bioartificial liver. Int J Artif Organs (submitted).
47. Nyberg SL, Remmel RP, Mann HJ, Peshwa MV, Hu WS, Cerra FB. Primary hepatocytes outperform Hep G2 cells as the source of biotransformation functions in a bioartificial liver. Ann Surg 1994; 220: 59-67.
48. Nyberg SL, Hibbs JR, Hardin TA, Germer TJ, Persing DH. Transfer of porcine endogenous retrovirus across hollow fiber membranes: Significance to a bioartificial liver. Transplantation 1999; 69: 1251-5.
49. Pitkin Z, Mullon C. Evidence of absence of porcine endogenous retrovirus (PERV) infection in patients treated with a bioartificial liver support system. Artif Organs 1999; 23: 829-33.
50. Paradis K, Langford GA, Long Z, et al. Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue. The XEN 111 Study Group. Science 1999; 285: 1236-41.